『Optometric Insights Media』のカバーアート

Optometric Insights Media

Optometric Insights Media

著者: Dr. Dave Kading & Dr. Mile Brujic
無料で聴く

Optometric Insights Media aims to provide you clinical cases, latest in optometry and other resources that could help you ACCELERATE YOUR SUCCESS in Optometry.

© 2026 Optometric Insights Media
マネジメント マネジメント・リーダーシップ 経済学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • #110 The Myopia Podcast - How to develop a unique myopia practice with Dr. Chris Browning
    2026/09/07

    Send us Fan Mail

    About Dr. Browning

    Christopher J. Browning, OD, is a Greenwood native who is proud to follow his dream of providing eye care to his wonderful community. As he has severe nearsightedness, Dr. Browning is passionate about using cutting-edge technology to help his patients achieve excellent vision, particularly through contact lenses.

    Learn more

    続きを読む 一部表示
    25 分
  • #204 The OI Show - The 11-Star Patient Experience: Inside Dr. Sian's Service Playbook with Dr. Harbir Sian
    2026/08/18

    Send us Fan Mail

    About Dr. Harbir Sian OD

    Dr. Harbir Sian is the co-owner of three optometric practices in British Columbia. In the clinic, Dr. Sian enjoys practicing various specialties within eyecare, particularly myopia management and dry eye.

    After completing his Doctor of Optometry degree from the New England College of Optometry in 2010, Dr. Sian found that he was passionate about giving back to those who have less access to care and about educating the public and professionals in various settings.

    Over the years, Harbir has volunteered in multiple mobile vision clinics, including global clinics South America and in the Middle East. He has taken his passion for education to countless stages and conferences around North America, including giving a TEDx talk titled "Our Eyes Are The Windows to Our Soul”, which shared the magic and power of the human visual system. Harbir was named as one of the Contact Lens Institute’s 2025 Visionaries. He is also the host of Canada’s number 1 optometry podcast, The 20/20 Podcast which showcases successful guests from various industries and backgrounds.

    続きを読む 一部表示
    23 分
  • #203 The OI Show - Pain With No Stain: The Eye Condition Most Doctors Get Wrong With Bob Dempsey
    2026/08/04

    Send us Fan Mail

    Mr. Dempsey brings more than two decades of domestic and global experience in the ophthalmic space, driving successful drug development, business transactions, and commercialization. Mr. Robert’s CEO and Board Director experience spans extensive transaction and portfolio expertise across venture capital, investment banking, and strategies to successfully secure funding and advance M&A opportunities for multiple companies. His professional network in the eye care community is broad and well-established, complemented by his philanthropic leadership as Co-Founder and Board Member of the Holland Foundation for Sight Restoration. Robert also serves as an independent director on multiple ophthalmic
    Boards.

    Mr. Dempsey currently serves as Chief Executive Officer of OKYO Pharma, a public, clinical-stage biopharmaceutical company developing investigational therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases. The company’s lead candidate, urcosimod, has received FDA Fast Track designation for treating NCP. Previously, Mr. Dempsey served as Interim Chief Executive Officer of Ashvattha Therapeutics, where he led development of Migaldendranib (MGB), a novel targeted nanomedicine platform designed to normalize VEGF expression for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Earlier in his career, Mr. Dempsey served as President and Chief Executive Officer of AsclepiX Therapeutics, where he oversaw the rapid clinical development of a new chemical entity targeting ocular diseases and cancer through naturally occurring, self-regulating homeostatic pathways. Prior to that, he served as Chief Executive Officer of TearClear, where he accelerated the company’s business and commercial strategy, leading to multiple value-inflection points, including a successful Series B financing and positive FDA engagements.

    Mr. Dempsey formerly served as the Group Vice President and Head of Global Ophthalmology at Shire, which was acquired by Takeda, and was responsible for closing one of only 3 ophthalmology transactions with >$1B upfront in the last 2 decades for Xiidra that transacted again 4 years later for $1.7B to Bausch & Lomb.
    At Shire, he swiftly established a highly regarded reputation for Shire as a new company in the ophthalmology and optometry markets. Leading the commercialization strategy that resulted in an industry-leading launch, while overseeing the acquisition of four companies that contributed to the franchise pipeline of innovative candidates aimed at improving vision-related quality, was an
    accomplishment about which he is most proud.

    In his spare time, he enjoys spending time with family on the lake and watching Boston sports.


    Here's another episode about neuropathic pain on The OI Show: https://theoishow.buzzsprout.com/1601521/episodes/15618641-167-the-oi-show-neuropathic-pain-with-kaleb-abbott

    続きを読む 一部表示
    18 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません